Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00878592
Other study ID # PRO08010154
Secondary ID non applicable
Status Terminated
Phase N/A
First received April 8, 2009
Last updated October 9, 2017
Start date October 2008

Study information

Verified date April 2009
Source University of Pittsburgh
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is to assess value of providing classes about dietary and life style modifications to decrease or prevent weight gain, less occurrence or better control of weight gain associated disorders such as high blood sugar, hypertension, heart or brain vessels problems.Candidates for this study will be those who have got liver transplant within 6 months of their post transplant period.


Description:

This study is designed to be an interventional, prospective, randomized, case-control clinical trial. Procedures will be done in Starzl Transplant Institute and Center for Liver disease, Kaufmann building, UPMC.

Subjects selected to participate in this study, are adult liver transplant recipients who had undergone one liver transplantation during 6 months before the time of inclusion. They must be able to communicate in English (to be able to independently follow directives and record their activities in recall diaries). Patients will be excluded from the study if they are under 18 years old, refuse to give a written consent to participate in the study, have received liver graft more than 6 months before time of inclusion, have psychological or nervous disorders, have cardiovascular or musculoskeletal health problems interfering with basic physical activity, or have any manifestation of hepatic failure such as ascites and hepatic encephalopathy. Patients will be removed from the study if they develop intolerance to the dietary and physical recommendations (e.g. remarkable fatigue).

Verifying the eligibility of patients for participation in the study will be done through reviewing data in medical history, physical examination and investigations included in the patients' medical records. Complete blood count, liver function tests, fasting glucose and lipid profile, imaging and histopathologic investigations, abdominal imaging, pathology reports of liver biopsy, stress ECG, echocardiography. These tests are performed for standard of care.

Subjects will be randomly grouped into groups by simple randomization method. One of the investigators will randomly pick one folded paper out of a plastic bag that contains folded papers labeled on the folded side with the number of the group.

The first group (Group 1) will include the control subjects. They will receive one session of dietary and behavioral education. The second group (Group 2) will be the interventional group. They will receive a weight management and life style modification program similar to what has been previously described (Kelley et al. 2004). The program will be presented by a registered dietitian at UPMC". It consists of up to 6 weekly sessions of nutritional and physical exercise education. These initial sessions will concentrate on lifestyle modifications program including healthy food selections, emphasizing reduced fat consumption (<=30% of daily calories) and restriction of proteins to create a daily negative energy balance of ~500 kcal/day. Participants will be encouraged to start with 10 minutes of outdoor or at home physical activity such as walking or cycling then gradually increase the activity duration up to 30 minutes daily. The dietitian will provide each subject with diary for daily recording of dietary intake and physical activity respectively. Following the initial 6-week program patients will attend follow up session every 6 months for 5 years for dietary and behavioral education and to check dietary and physical activity diaries, reinforce and encourage compliance with dietary and physical exercise recommendations, answer questions and address problems. Patients will be required to attend at least 60% of the follow up sessions on site with face to face education. Attempts will be made to schedule these sessions on the same day of their regular clinical follow up to facilitate compliance. Up to 40% of monthly follow up sessions may be provided on the phone for patients who cannot attend on site because of travel restraints. The dietitian will call the candidate within few days after the missing appointment to check and encourage compliance, check for changes in weight. Each session will be held for up to 1 hour at the health education room of center for liver diseases. All sessions will be with a registered dietitian.

Additional 5 cc of blood will be taken at routine blood draws done twice in the first month then every 6 months for 5 years. The total blood volume withdrawn from each subject in both study groups is 60 cc. Blood will be spinned down, then serum will be banked in -80° Celsius freezer. These banked serum will be used in future research work aiming to assess activity of inflammatory and fibrotic markers such as tumor necrosis factor alpha, interleukin 6, leptin, and adiponectin.

Stool samples will be taken from all patients before study intervention and every 12 weeks afterwards. Stool samples will be stored at -80 degree Celsius freezer for future PCR study of fecal microflra.

Jennifer Steel will assess stress for the study candidates through specific questionnaire before start of intervention of the study and every 12 weeks afterwards.

The following data will be collected every 6 months during follow up visits for both groups; anthropometric indices of obesity such as measurements of weight, height (for BMI calculation), waist circumference, hip circumference, skin fold thickness and mid-arm circumference, survival rate, morbidity events such as cardiovascular or cerbrovascular events, diabetes and hypertension. For the control group, anthropometric measures will be obtained from them when they return for their routine clinic visits. Midarm circumference and triceps skin fold thickness will be measured to the nearest 1 cm, on the left arm midway between the tip of the acromion and the tip of olecranon. Skinfold thicknesses will be measured at triceps (Oppert et al. 2002). Waist circumference will be measured midway between iliac crest and lowest rib margin, and hip circumference at the level of the greater trochanters (Han et al. 2001).

Histological scores of necro-inflammation (Ishak score) and steatosis (Dixon's scale) of the implanted liver will be assessed at 1 year post transplant. All pathological evaluation will be done on parts (allocated for the research purpose) of biopsies obtained as deemed necessary for routine care by clinical providers (e.g. at 1 year post liver transplant) and will be conducted by the same pathologist blinded to the experimental protocol.

Data will be compared between the 2 groups by Chi square test and student t test . Assuming a rate of obesity in the control group of 50% and a 50% reduction of obesity incidence in the interventional group, we estimate that a sample size of 58 per group is needed to detect the difference with 80% confidence and a p value < 0.05. A p< 0.05 will be considered significant.


Recruitment information / eligibility

Status Terminated
Enrollment 0
Est. completion date
Est. primary completion date June 2010
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Adult liver transplant recipients

- Those who have undergone one liver transplantation during 3 months before the time of inclusion.

- Ability to communicate in English (to be able to independently follow directives and record their activities in recall diaries).

Exclusion Criteria:

- Patients under 18 years old

- refusal to give a written consent to participate in the study

- Those who received liver graft more than 3 months before time of inclusion

- Significant cardiovascular or musculoskeletal health problems interfering with basic physical activity

- Any manifestations of hepatic failure such as ascites and hepatic encephalopathy

- Patients will be removed from the study if they develop intolerance to the dietary and physical recommendations (e.g. remarkable fatigue).

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Dietary and life style modification
This group will receive a weight management and life style modification program. It consists of up to 6 weekly sessions of nutritional and physical exercise education. These initial sessions will concentrate on lifestyle modifications program including healthy food selections, emphasizing reduced fat consumption (<=30% of daily calories) and restriction of proteins to create a daily negative energy balance of ~500 kcal/day. Participants will be encouraged to start with 10 minutes of outdoor or at home physical activity such as walking or cycling then gradually increase the activity duration up to 30 minutes daily.

Locations

Country Name City State
United States Center for Liver Diseases, UPMC. Pittsburgh Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
University of Pittsburgh

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary waist circumference before starting intervention, then every 6 months, afterwards for up to 5 years
Primary weight, height (for BMI calculation) before starting intervention, then every 6 months, afterwards for up to 5 years
Secondary skin fold thickness before starting intervention, then every 6 months, afterwards for up to 5 years
Secondary survival rate anually for up to 5 years
Secondary Co morbidity events anually for up to 5 years
Secondary histological scores of necro-inflammation (Ishak score) and steatosis (Dixon's scale) of the implanted liver. at 1 year from start of inclusion
See also
  Status Clinical Trial Phase
Completed NCT03375008 - Predictable MR Index for Nonalcoholic Steatohepatitis (NASH) N/A
Recruiting NCT05979779 - Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis Phase 2
Withdrawn NCT02769091 - A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes Phase 2
Completed NCT02654977 - CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Metreleptin in Various Forms of Partial Lipodystrophy Phase 2
Recruiting NCT05211284 - Saroglitazar Magnesium 4 mg for NASH in People Living With HIV in the US Phase 2
Completed NCT02421094 - Clinical Trial to Evaluate Efficacy of GR-MD-02 for Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis Phase 2
Completed NCT01205087 - Safety and Efficacy of Oral Administration of Anti-CD3 Monoclonal Antibody (mAb)in Patients With the Metabolic Syndrome Phase 2
Recruiting NCT00152711 - Impact of nCPAP Treatment on Liver Function in Patients With Sleep Apnea Syndrome and Nonalcoholic Steatohepatitis N/A
Completed NCT02217475 - Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver Fibrosis Phase 2
Completed NCT04031729 - Aspirin for the Treatment of Nonalcoholic Fatty Liver Disease Phase 1/Phase 2
Completed NCT03674476 - An Investigational Study to Evaluate Experimental Medication BMS-986036 in Participants With Different Levels of Kidney Function Phase 1
Recruiting NCT03725631 - Non-invasive Evaluation of Liver Fibrosis, Steatosis, and NASH in NAFLD N/A
Terminated NCT04565717 - A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) Phase 1
Completed NCT01679197 - Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy Phase 2
Active, not recruiting NCT05084404 - Efficacy and Safety of Guanabenz for Nonalcoholic Fatty Liver Disease Phase 2
Active, not recruiting NCT02574325 - A Study to Assess ARI-3037MO on Hepatic Fat Metabolism in Patients With Dysglycemia and Evidence of Hepatic Steatosis Phase 2
Recruiting NCT02148471 - Fatty Acids, Genes and Microbiota in Fatty Liver N/A
Completed NCT00227110 - Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH) Phase 4
Completed NCT03656744 - A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM) Phase 2
Completed NCT03068078 - A Reduced-carbohydrate Diet High in Monounsaturated Fats in Type 2 Diabetes N/A